Alexion Pharmaceuticals, Inc. (ALXN) Stake Lifted by Securian Asset Management Inc

Share on StockTwits

Securian Asset Management Inc raised its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 23,131 shares of the biopharmaceutical company’s stock after purchasing an additional 441 shares during the period. Securian Asset Management Inc’s holdings in Alexion Pharmaceuticals were worth $2,252,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of ALXN. Jennison Associates LLC lifted its position in shares of Alexion Pharmaceuticals by 43.1% in the 3rd quarter. Jennison Associates LLC now owns 8,627,536 shares of the biopharmaceutical company’s stock worth $1,199,314,000 after purchasing an additional 2,599,414 shares during the period. FMR LLC lifted its position in shares of Alexion Pharmaceuticals by 8.1% in the 3rd quarter. FMR LLC now owns 21,096,993 shares of the biopharmaceutical company’s stock worth $2,932,693,000 after purchasing an additional 1,581,376 shares during the period. American Century Companies Inc. lifted its position in shares of Alexion Pharmaceuticals by 164.2% in the 3rd quarter. American Century Companies Inc. now owns 1,904,296 shares of the biopharmaceutical company’s stock worth $264,716,000 after purchasing an additional 1,183,476 shares during the period. Iridian Asset Management LLC CT lifted its position in shares of Alexion Pharmaceuticals by 58.1% in the 3rd quarter. Iridian Asset Management LLC CT now owns 2,365,078 shares of the biopharmaceutical company’s stock worth $328,769,000 after purchasing an additional 868,886 shares during the period. Finally, Clearbridge Investments LLC lifted its position in shares of Alexion Pharmaceuticals by 15.4% during the 3rd quarter. Clearbridge Investments LLC now owns 5,178,157 shares of the biopharmaceutical company’s stock valued at $719,816,000 after acquiring an additional 691,390 shares during the period. Hedge funds and other institutional investors own 93.33% of the company’s stock.

ALXN has been the topic of a number of research reports. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Credit Suisse Group reiterated a “buy” rating and set a $156.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, December 21st. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $134.00 target price on the stock in a research report on Tuesday, October 30th. Raymond James reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, December 30th. Finally, ValuEngine upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 8th. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $162.31.

Shares of ALXN stock opened at $120.14 on Friday. The firm has a market cap of $26.85 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 0.89 and a beta of 1.56. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.88 and a quick ratio of 2.74. Alexion Pharmaceuticals, Inc. has a 12 month low of $92.56 and a 12 month high of $140.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 EPS for the quarter, beating the Zacks’ consensus estimate of $1.60 by $0.54. The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. Alexion Pharmaceuticals’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.48 EPS. Analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.51 EPS for the current year.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 3,244 shares of the business’s stock in a transaction on Monday, December 31st. The shares were sold at an average price of $95.85, for a total transaction of $310,937.40. Following the completion of the sale, the chief executive officer now owns 150,696 shares in the company, valued at approximately $14,444,211.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Indrani Lall Franchini sold 2,605 shares of the business’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total transaction of $307,728.65. Following the sale, the executive vice president now owns 29,304 shares of the company’s stock, valued at approximately $3,461,681.52. The disclosure for this sale can be found here. Insiders have sold a total of 9,093 shares of company stock valued at $929,603 in the last 90 days. 4.35% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Stake Lifted by Securian Asset Management Inc” was reported by Fairfield Current and is owned by of Fairfield Current. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.fairfieldcurrent.com/news/2019/02/10/alexion-pharmaceuticals-inc-alxn-stake-lifted-by-securian-asset-management-inc.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

See Also: What is the Bid-Ask Spread?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply